多级孔芳香骨架材料的合成及固载硫脲催化剂的研究

合成了一种多级孔芳香骨架材料(PAF-70); 使用由氨基修饰过的单体, 应用该合成策略得到了同样具有窄分布介孔的含有氨基活性位点的PAF材料, 并通过硫脲单体与其氨基活性位点的反应, 将硫脲基团引入PAF-70材料中, 获得了含有硫脲催化位点的材料(PAF-70-thiourea). 氮气吸附-脱附测试结果显示, PAF-70存在孔径分布较窄的介孔, 介孔孔径为3.8 nm, 与模拟计算值(约3.7 nm)吻合. 热重分析结果表明, PAF-70具有很高的热稳定性. PAF-70在大多数溶剂中可以稳定存在, 具有良好的化学稳定性. 将PAF-70-thiourea作为催化剂, 应用在N-溴代琥珀酰亚胺(NBS)氧化醇类的反应中, 其表现出较高的催化活性、 较高的稳定性和广泛的底物适用性. 与含有相同硫脲催化位点的金属有机框架(MOF)材料(IRMOF-3-thiourea)作为催化剂对比, 进一步证实PAFs材料非常适合作为催化有机反应的固载平台.     

政府监管下的医院医疗信息分享演化博弈分析

在分析政府监管下医院间医疗信息分享特征的基础上,结合我国当前正在推行的医联体医院间信息分享运作模式,引入梅特卡夫定律并考虑患者评价的影响,分析了监管部门与医院各自的利益组成,建立了监管部门与医院两者之间的演化博弈模型,并采用复制动态方程研究了不同情形下医院间信息分享的演化博弈轨迹。研究表明,政府通过监管并建立激励惩罚机制等引导措施对医院最终达到的演化稳定态具有极大影响;降低医院主体信息分享的风险成本、规范提高医院分享信息的质量、引导患者增强对医院信息分享的关注、制定有吸引力和威慑力的奖惩政策,是促进医院医疗信息分享的关键。研究结果可为政府监管部门预测医院间的信息分享趋势和制定精准化政策以促进分享提供参考。     

Aromatic 19F–13C TROSY—[19F, 13C]-Pyrimidine Labeling for NMR Spectroscopy of RNA

We present the access to [5-¹⁹F, 5-¹³C]-uridine and -cytidine phosphoramidites for the production of site-specifically modified RNAs up to 65 nucleotides (nts). The amidites were used to introduce [5-¹⁹F, 5-¹³C]-pyrimidine labels into five RNAs—the 30 nt human immunodeficiency virus trans activation response (HIV TAR) 2 RNA, the 61 nt human hepatitis B virus ϵ (hHBV ϵ) RNA, the 49 nt SAM VI riboswitch aptamer domain from B. angulatum, the 29 nt apical stem loop of the pre-microRNA (miRNA) 21 and the 59 nt full length pre-miRNA 21. The main stimulus to introduce the aromatic ¹⁹F–¹³C-spin topology into RNA comes from a work of Boeszoermenyi et al., in which the dipole-dipole interaction and the chemical shift anisotropy relaxation mechanisms cancel each other leading to advantageous TROSY properties shown for aromatic protein sidechains. This aromatic ¹³C–¹⁹F labeling scheme is now transferred to RNA. We provide a protocol for the resonance assignment by solid phase synthesis based on diluted [5-¹⁹F, 5-¹³C]/[5-¹⁹F] pyrimidine labeling. For the 61 nt hHBV ϵ we find a beneficial ¹⁹F–¹³C TROSY enhancement, which should be even more pronounced in larger RNAs and will facilitate the NMR studies of larger RNAs. The [¹⁹F, ¹³C]-labeling of the SAM VI aptamer domain and the pre-miRNA 21 further opens the possibility to use the biorthogonal stable isotope reporter nuclei in in vivo NMR to observe ligand binding and microRNA processing in a biological relevant setting.     

Well-posedness for the massive nonlinear wave equation on asymptotically AdS spacetimes

In this paper, we prove some well-posedness theorems for the nonlinear massive wave equation (with the mass satisfying the Breitenlohner-Freedman bound) on asymptotically anti-de Sitter spaces. The solution is constructed by contraction mapping method and also as a limit of solutions to an initial boundary value problem with boundary at a finite location in spacetime by finally pushing the boundary out to infinity. The solution obtained is unique within the energy class.     

GOSs-稀土配合物紫外增强材料的光谱分析与稳定性研究

氧化石墨烯薄片(GOSs)作为一种新型的二维片状材料,具有较高的比表面积、丰富的表面含氧官能团以及良好的光热稳定性。而稀土配合物通过无机稀土元素与有机配体的结合表现出优异的荧光特性。为了将两类材料具有的物化特性结合起来应用于紫外光谱探测领域。选取了合适的有机配体啉菲罗啉(1,10-邻二氮杂菲,phen)、2’2-联嘧啶(bpm)作为桥联分子,把氧化石墨烯(GOSs)与稀土配合物通过氢键自组装作用进行复合,制备了高效稳定可调的GOSs-稀土配合物复合荧光材料GOSs-Eu(BA)3phen和GOSs-Eu(TTA)3bpm,并且制备了相应的聚乙烯醇(PVA)共混紫外增强薄膜,对其光谱特性与稳定性进行了深入的研究。采用红外光谱、扫描电镜和金相显微镜等方法,对紫外增强材料进行了性能表征。采用吸收光谱,荧光光谱等方法,对紫外增强薄膜进行了性能表征。此外,通过热重测试(TGA)表征了GOSs氢键复合前后紫外增强材料的热稳定性,通过荧光强度-紫外光照次数表征了GOSs氢键复合前后紫外增强薄膜的光稳定性。红外光谱分析发现,进行配位前后有机配体的特征峰产生了频移,表明稀土配合物中Eu 3+与配体之间存在着明显的配位作用。在进行复合之后,桥联配体的特征峰也产生了偏移,表明GOSs与稀土配合物通过桥联分子的氢键作用进行了进行复合。吸收光谱与荧光光谱测定结果表明增强薄膜吸收峰在200~400 nm,荧光主峰在612 nm左右,为Eu 3+特征红色荧光峰,且不同配体可以实现不同范围的吸收产生差异化的荧光表现。扫描电镜和金相显微镜清晰地展示了稀土配合物复合前后的微观形貌,即颗粒状稀土配合物附着在石墨烯薄片上。光稳定性测试表明经过GOSs氢键复合之后,Eu(BA)3phen和Eu(TTA)3bpm稀土配合物荧光材料在进行25次荧光强度测试后光漂白程度分别下降了4.26%和6.41%,提高了其光稳定性。热重测试也表明在经过GOSs氢键复合之后,稀土配合物的热稳定性有了很大提高。总之,得益于GOSs和稀土配合物的特性结合,所制备的紫外增强材料表现出优异的荧光特性与稳定性,必将在紫外探测方面有着广阔的应用前景。     

Ultrathin Mn Doped Ni-MOF Nanosheet Array for Highly Capacitive and Stable Asymmetric Supercapacitor

In this study, we demonstrate that an Mn-doped ultrathin Ni-MOF nanosheet array on nickel foam (Mn_0.1-Ni-MOF/NF) serves as a highly capacitive and stable supercapacitor positive electrode. The Mn_0.1-Ni-MOF/NF shows an areal capacity of 6.48 C cm⁻² (specific capacity C: 1178 C g⁻¹) at 2 mA cm⁻² in 6.0 m KOH, outperforming most reported MOF-based materials. More importantly, it possesses excellent cycle stability to maintain 80.6 % capacity after 5000 cycles. An asymmetric supercapacitor device utilizing Mn_0.1-Ni-MOF/NF as the positive electrode and activated carbon as the negative electrode attains a high energy density of 39.6 Wh kg⁻¹ at 143.8 Wkg⁻¹ power density with a capacitance retention of 83.6 % after 5000 cycles.     

Establishment and validation of an SIL-IS LC–MS/MS method for the determination of ibuprofen in human plasma and its pharmacokinetic study

In this work, we developed and validated a highly sensitive, rapid and stable LC–MS/MS method for the determination of ibuprofen in human plasma with ibuprofen-d3 as a stable isotopically labeled internal standard (SIL-IS). Human plasma samples were prepared by one-step protein precipitation. The chromatographic separation was achieved on a Poroshell 120 EC-C₁₈ (2.1 × 50 mm, 2.7 μm). Aqueous solution (containing 0.05% acetic acid and 5 mm NH₄Ac) and methanol were selected as the mobile phase with gradient elution. An electrospray ionization source was applied and operated in negative ion mode. Multiple reaction monitoring mode was used for quantification using target fragment ions m/z 205.0 → 161.1 for ibuprofen and m/z 208.0 → 164.0 for SIL-IS, respectively. This method exhibited a linear range of 0.05–36 μg/ml for ibuprofen with correlation coefficient >0.99. Mean recoveries of ibuprofen in human plasma ranged from 78.4 to 80.9%. The RSD of intra- and inter-day precision were both < 5%. The accuracy was between 88.2 and 103.67%. The matrix effect was negligible in human plasma, including lipidemia and hemolytic plasma. A simple, efficient and accurate LC–MS/MS method was successfully established and applied to a pharmacokinetic study in healthy Chinese volunteers after a single oral administration of ibuprofen granules.